These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. Fucikova J; Coosemans A; Orsulic S; Cibula D; Vergote I; Galluzzi L; Spisek R J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34645669 [TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis. Yang S; Zhao H; Xiao W; Shao L; Zhao C; Sun P J Gene Med; 2022 Oct; 24(10):e3446. PubMed ID: 36027869 [TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H Front Immunol; 2022; 13():956224. PubMed ID: 36032075 [TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043 [TBL] [Abstract][Full Text] [Related]
6. Exosomes released from M2 macrophages transfer miR-221-3p contributed to EOC progression through targeting CDKN1B. Li X; Tang M Cancer Med; 2020 Aug; 9(16):5976-5988. PubMed ID: 32590883 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy. Wang Y; Zhang L; Bai Y; Wang L; Ma X Front Immunol; 2022; 13():1036298. PubMed ID: 36341388 [TBL] [Abstract][Full Text] [Related]
8. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer. Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542 [TBL] [Abstract][Full Text] [Related]
9. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151 [TBL] [Abstract][Full Text] [Related]
10. In Vivo Analysis of Tumor-Associated Macrophages in the Tumor Microenvironment. Anfray C; Ummarino A; Calvo A; Allavena P; Torres Andón F Methods Mol Biol; 2023; 2614():93-108. PubMed ID: 36587121 [TBL] [Abstract][Full Text] [Related]
12. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Chu X; Tian Y; Lv C Mol Cancer; 2024 Jul; 23(1):150. PubMed ID: 39068459 [TBL] [Abstract][Full Text] [Related]
13. Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages. Alsina-Sanchis E; Mülfarth R; Moll I; Böhn S; Wiedmann L; Jordana-Urriza L; Ziegelbauer T; Zimmer E; Taylor J; De Angelis Rigotti F; Stögbauer A; Giaimo BD; Cerwenka A; Borggrefe T; Fischer A; Rodriguez-Vita J Cancer Res; 2022 Dec; 82(23):4414-4428. PubMed ID: 36200806 [TBL] [Abstract][Full Text] [Related]
14. Siglec-9 Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296 [TBL] [Abstract][Full Text] [Related]
15. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer. Zhu Q; Wu X; Wu Y; Wang X Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885 [TBL] [Abstract][Full Text] [Related]
16. Targeting tumor-associated macrophages for cancer immunotherapy. Cao X; Lai SWT; Chen S; Wang S; Feng M Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930 [TBL] [Abstract][Full Text] [Related]
17. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. Gao J; Liang Y; Wang L Front Immunol; 2022; 13():888713. PubMed ID: 35844605 [TBL] [Abstract][Full Text] [Related]
18. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871 [TBL] [Abstract][Full Text] [Related]
19. The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool For Ovarian Cancer Immunotherapy Research. Rodriguez GM; Galpin KJC; Cook DP; Yakubovich E; Maranda V; Macdonald EA; Wilson-Sanchez J; Thomas AL; Burdette JE; Vanderhyden BC Cancer Res Commun; 2022 Jun; 2(6):417-433. PubMed ID: 36311166 [TBL] [Abstract][Full Text] [Related]
20. Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Zhou J; Li X; Wu X; Zhang T; Zhu Q; Wang X; Wang H; Wang K; Lin Y; Wang X Cancer Immunol Res; 2018 Dec; 6(12):1578-1592. PubMed ID: 30396909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]